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ABSTRACT 46 
This document provides recommendations for monitoring and treatment of children in whom 47 
bronchopulmonary dysplasia (BPD) has been established and were discharged from the 48 
hospital, or who were older than 36 weeks of postmenstrual age. The guideline was based 49 
on pre-defined Population, Intervention, Comparison and Outcomes (PICO) questions 50 
relevant for clinical care, a systematic review of the literature, and assessment of the 51 
evidence using the Grading of Recommendations, Assessment, Development and 52 
Evaluation (GRADE) approach. After considering the balance of desirable (benefits) and 53 
undesirable (burden, adverse effects) consequences of the intervention, the certainty of the 54 
evidence, and values, the Task Force made conditional recommendations for monitoring and 55 
treatment of BPD based on very low to low quality of evidence. We suggest monitoring with 56 
lung imaging using ionising radiation in a subgroup only, for example severe BPD or 57 
recurrent hospitalizations, and monitoring with lung function in all children. We suggest to 58 
give individual advice to parents regarding day care attendance. With regards to treatment, 59 
we suggest to use bronchodilators in a subgroup only, for example asthma-like symptoms, or 60 
reversibility in lung function, no treatment with inhaled or systemic corticosteroids, natural 61 
weaning of diuretics by the relative decrease in dose with increasing weight gain if diuretics 62 
are started in the neonatal period, and to treat with supplemental oxygen with a saturation 63 
target range of 90-95%. A multidisciplinary approach for children with established severe 64 
BPD after the neonatal period into adulthood is preferable. These recommendations should 65 
be considered until new and urgently needed evidence becomes available. 66 
67 
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INTRODUCTION  68 
Bronchopulmonary dysplasia (BPD), also called chronic lung disease of prematurity, is a 69 
chronic respiratory disease that predominantly affects children born preterm. Advanced 70 
perinatal care has improved the survival of extremely preterm born children, however the 71 
incidence of BPD has not decreased (1). Improved survival is mainly due to the introduction 72 
of antenatal management, including maternal corticosteroid administration, intratracheal 73 
surfactant administration, less aggressive mechanical ventilation strategies and targeted 74 
oxygen therapy, which consequently led to a different form of BPD (2-26). Since 1999, BPD 75 
is defined as oxygen need for ≥28 days from birth until 36 weeks of postmenstrual age 76 
(PMA) (27, 28). Whilst in earlier years BPD was associated with aggressive mechanical 77 
ventilation, improved ventilation changed the histologic phenotype of BPD from a 78 
predominantly post-traumatic condition leading to the formation of hyaline membranes (old 79 
form of BPD), to one where pulmonary changes are characterized by a global alveolar 80 
development arrest (new form of BPD) (27, 29). The precise maturational trajectory of 81 
airways, lungs and related vessels in extreme preterm, early extra-uterine life is not fully 82 
known but is likely to comprise airway, lung, and vascular driven pathology leading to severe 83 
chronic respiratory and vascular diseases across the life course, and potentially shorten life 84 
expectancy. Once discharged from the neonatal unit, children with BPD are at a high risk of 85 
re-hospitalization due to higher susceptibility of viral infections, decreased nutritional state or 86 
poorer neurological outcome, leading to increased health care utilization and costs (30). 87 
Apart from advising on preventative measures, the application of supportive measures is 88 
paramount. Therefore, physicians and caretakers need to assess the disease progression 89 
and tailor treatment adequately. Also, previous studies showed that children with BPD have 90 
an impaired lung structure, lower lung function, including declining lung function over time, 91 
and increased risk of respiratory symptoms in later life (31-41). This suggests that BPD partly 92 
reflects an ongoing chronic respiratory disease with long-term consequences and not just 93 
stabilized structural lung damage after the neonatal period. BPD in childhood may form a 94 
new group of chronic obstructive pulmonary disease (COPD) in adulthood.  95 
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 Although several tools have been studied for their utility in monitoring children with 96 
BPD, to date, there are no guidelines on comprehensive monitoring strategies for children in 97 
whom BPD has been established and who are discharged from the hospital (42, 43). Further, 98 
most studies have so far largely focused on preventing, rather than treating established BPD. 99 
Interventional studies beyond the neonatal period, such as use of inhaled or systemic 100 
corticosteroids, bronchodilators and long-term oxygen treatment, are far and few available. A 101 
clear consensus and recommendations with grading evidence on how to monitor and treat 102 
children with BPD at the long term is lacking. 103 
 Therefore, we undertook a systematic review of the literature and developed 104 
recommendations following the Grading of Recommendations Assessment, Development 105 
and Evaluation (GRADE)(44), to inform decisions regarding the monitoring and treatment of 106 
children with BPD. Specifically, we focused on those children with the new form of BPD in 107 
whom BPD already had been established and were discharged from the hospital, or who 108 
were older than 36 weeks of postmenstrual age. This population is meant when referring to 109 
children with BPD throughout this manuscript. The target audience of this guideline includes 110 
specialists in respiratory medicine, pediatricians and/or neonatologists who manage children 111 
with bronchopulmonary dysplasia. Other healthcare physicians such as respiratory nurses 112 
and policy makers may also benefit from this guideline. This guideline provides the basis for 113 
rational decisions in the monitoring and treatment of specifically children in whom BPD has 114 
been established and who were discharged from the hospital, or were older than 36 weeks of 115 
PMA. Clinicians, patients and their parents/care-givers, third-party payers, stakeholders or 116 
the courts should never view the recommendations contained in these guidelines as 117 
mandatory. Though evidence-based guidelines can summarize the best available evidence 118 
regarding the effects of an intervention in a given patient population, they cannot take into 119 
account all of the unique clinical circumstances that may arise when managing an individual 120 
patient.121 
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Methods  122 
Task Force composition The chairs applied for a Task Force on BPD, which was approved 123 
and funded by the European Respiratory Society. The Task Force consisted of a 124 
multidisciplinary group of clinicians, scientific researchers, methodologists or patient 125 
representatives with expertise in the pediatric respiratory (n=11), neonatology (n=3), pediatric 126 
cardiology (n=1), adult respiratory (n=1), epidemiology (n=3), and patient involvement (n=4) 127 
field related to long term monitoring and treatment of children with BPD. All representatives 128 
had intensive experience in long term follow-up of children born preterm or with BPD. Task 129 
Force members were from Europe, the United States and Australia. Two junior 130 
members/trainees of the ERS, a parent of a patient with BPD, an adult patient with BPD, and 131 
national (Lung Foundation Netherlands) and international (European Lung Foundation) 132 
patient representatives were active members of the committee. Also, methodologists from 133 
the ERS provided expertise in guideline development following the GRADE approach. 134 
Potential conflicts of interest were disclosed and managed according to ERS policies.  135 
 136 
Formulation of the topics and questions Task Force members compiled a list of topics 137 
that they considered important and relevant to the monitoring and treatment of children with 138 
established BPD after the neonatal period. Discussion among the Task Force members was 139 
applied to identify the eight most relevant and important questions to be addressed in this 140 
guideline. Questions related to the topics were phrased using the Population, Intervention, 141 
Comparison and Outcomes (PICO) format. The population (P) consisted specifically of 142 
children with the new form of BPD, in whom BPD had been established and who were 143 
discharged from the hospital, or were older than 36 weeks of PMA. The interventions (I) 144 
comprised monitoring with lung imaging or lung function, discouraging daycare attendance, 145 
and treatment with inhaled bronchodilators, inhaled corticosteroids, systemic corticosteroids, 146 
diuretics or oxygen. The comparison (C) were those without the intervention. Specific 147 
important and critical outcomes (O) defined for each question are presented in Table 1. The 148 
eight questions for children with BPD were:  149 
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1. Does monitoring with lung imaging versus no lung imaging; and 150 
2. Does monitoring with lung function versus no lung function; and 151 
3. Does discouraging day care attendance versus not discouraging day care attendance; 152 
and 153 
4. Does treatment with inhaled bronchodilators versus no inhaled bronchodilators; and 154 
5. Does treatment with inhaled corticosteroids versus no inhaled corticosteroids; and 155 
6. Does treatment with systemic corticosteroids versus no systemic corticosteroids; and 156 
7. Does treatment with diuretics versus no diuretics; and 157 
8. Does treatment with oxygen versus no oxygen;  158 
affect outcomes which are defined as important or critical? Thereafter, the questions ‘Does 159 
treatment with inhaled corticosteroids versus no inhaled corticosteroids’; and ‘Does treatment 160 
with systemic corticosteroids versus no inhaled corticosteroids affect important and critical 161 
defined outcomes’ were combined for practical reasons. For each question, a PICO working 162 
group was composed with a leader and two to four members.  163 
 164 
Rating the importance of outcomes The Task Force identified BPD morbidity and related 165 
outcomes after discharge or after 36 weeks of PMA that they considered relevant to each 166 
question. These comprised number and severity of respiratory symptoms, adverse growth, 167 
hospital admissions, CT abnormalities, reduced physical exercise capacity, pulmonary 168 
hypertension, use of inhaled bronchodilators, use of inhaled corticosteroids, use of systemic 169 
corticosteroids, use of diuretics, prolonged duration of supplemental oxygen need, side 170 
effects, adverse neurodevelopment, decreased quality of life, mortality, or impaired lung 171 
function, depending on each question under study. Task Force members rated the 172 
importance of each outcome a-priori, using a scale from 1 to 9. A rating of 1–3 was assigned 173 
to outcomes of low importance, 4–6 to outcomes important, and 7–9 to outcomes critical for 174 
decision-making. Individual ratings were summarized and evaluated by the co-chairs and an 175 
ERS methodologist. A final rating was proposed to all Task Force members, and approved. 176 
All outcomes were categorized as “not important”, “important” or “critical” for decision-making 177 
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(Supplementary Table 1). Only “important” or “critical” outcomes were used in the literature 178 
search and decision making (45).  179 
 180 
Literature search methods We conducted literature searches in Embase.com, Medline 181 
Ovid, Cochrane Central Registry of Trials, and Web of Science Core Collection until July 182 
11th, 2018 (last data search). We included meta-analyses and systematic reviews of 183 
randomised trials, randomised trials, and retrospective or prospective cohort studies 184 
published from 1999, in which BPD was defined. Detailed scripts of the search terms created 185 
by a librarian (WB) are given in the methods part of the Supplementary Material and 186 
Supplementary table 1. Scripts were set broad to limit missing of relevant articles. 187 
Conference abstracts were omitted.  188 
 189 
Study selection For each PICO question, working groups selected relevant articles in 3 190 
stages by: 1) title screening and abstract screening, 2) full article screening, and 3) reading 191 
full articles to summarize findings related to the PICO. A minimum of 2 group members were 192 
required to independently review the relevant articles to minimize potential bias. Inclusion 193 
criteria were the study population of children in whom BPD had been established and who 194 
were discharged from the hospital, or were older than 36 weeks of PMA, and studying the 195 
specifically defined monitoring and treatment tools in relation to the defined outcomes of 196 
interest. Exclusion criteria were incorrect population under study (no children, no BPD only 197 
as second best), incorrect monitoring or treatment intervention, study focused on prevention 198 
instead of monitoring or treatment of BPD, outcomes of interest not reported, no abstract or 199 
full text available, or no English text available. When no articles for the PICO directly fulfilled 200 
these criteria, indirect articles that indirectly fulfilled these criteria were included using a less 201 
favourable study design, preterm born children (as opposed to children with BPD) or the old 202 
form of BPD (as opposed to the new form of BPD). A discussion was held between the 203 
independent PICO working group members when no consensus was reached to include or 204 
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exclude identified articles. Also, 1 physician-epidemiologist (LD), 1 junior ERS member-205 
epidemiologist (EM), and 1 junior member-trainee (LM) read the identified articles, and 206 
discussed these to reach consensus on the selection of final articles if differences in opinion 207 
to in- or exclude the articles were present. When also no indirect articles for the PICO were 208 
found, experience of local, regional or national management of Task Force members was 209 
asked, summarized, and discussed if relevant.  210 
 211 
Evidence synthesis and grading With guidance from the ERS methodologists, relevant 212 
data were extracted from the selected studies for each PICO taking the outcomes into 213 
account that were rated “important” or “critical” for decision-making. We graded the effect 214 
estimates for the body of the evidence for each outcome to determine our certainty in the 215 
evidence, and presented the findings using the GRADEpro Guideline Development Tool 216 
(http://gdt.gradepro.org/app/). We primarily used findings from only one type of study design, 217 
preferably observational studies for monitoring questions and randomized trials (RCT) for 218 
treatment questions, to create a summary of evidence, and where appropriate used findings 219 
of other types of study designs to complement recommendations. Data were not amenable to 220 
pooling.  221 
 222 
Formulating recommendations The evidence profiles were sent to the Task Force 223 
members for review. Using an iterative consensus process conducted face to face and via 224 
email, recommendations were formulated on the basis of the balance of desirable (benefits) 225 
and undesirable (burden, adverse effect) consequences of the intervention, the certainty of 226 
the evidence, values, balance of effects, required resources, costs, equity, acceptability and 227 
feasibility, using the Evidence to Decision framework (46). Whether all domains could be 228 
assessed depended on the availability of the evidence per PICO. Recommendations could 229 
either be strong, or conditional (weak) (Table 2). A strong recommendation for an 230 
intervention was made when the Task Force was confident that the desirable effects 231 
outweighed the undesirable effects, while a strong recommendation against an intervention 232 
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was made when the Task Force was confident that the undesirable effects outweighed the 233 
desirable effects. A conditional recommendation for an intervention was made if the Task 234 
Force concluded that the desirable effects probably outweighed the undesirable effects, but 235 
was not confident, while a conditional recommendation against the intervention was made if 236 
the Task Force concluded that the undesirable effects probably outweighed the desirable 237 
effects, but was not confident.  238 
Reasons for making a conditional recommendation included low or very low certainty in the 239 
quality of evidence, a close balance between the desirable and undesirable consequences, 240 
or underlying values and preferences, equity, acceptability or feasibility in the direction 241 
opposite to that of the desirable effects (e.g. the desirable consequences of an intervention 242 
clearly outweigh the undesirable consequences taking into account that in some healthcare 243 
systems or situations the intervention is not widely acceptable or feasible to implement).  244 
  245 
Manuscript preparation The initial draft of the manuscript was prepared by the physician-246 
epidemiologist (LD) and a junior ERS member-epidemiologist (EM), and reviewed by a 247 
methodologist. Thereafter, both the manuscript and the online supplement were reviewed, 248 
edited and approved by all Task Force members prior to submission. 249 
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RESULTS 250 
The results of the evidence assessment are presented in Supplementary Tables 3.1 to 3.4. A 251 
summary of the recommendations is presented in Table 3. For each question, the number of 252 
potentially relevant papers ranged from 197 to 4,329, and of final papers from four to none. 253 
When formulating the recommendations, required resources, costs, equity, acceptability and 254 
feasibility were not taken into account due to lack of evidence.  255 
 256 
Review of evidence addressing the question on lung imaging 257 
PICO 1 In children with BPD, does monitoring with lung imaging versus no lung imaging 258 
affect important and critical defined outcomes? 259 
 260 
Summary of the evidence No direct evidence that would answer this question in an 261 
appropriate way was identified. Indirect evidence was provided by four studies that examined 262 
the relation of lung imaging with lung function or duration of supplemental oxygen need 263 
(Supplementary Table 3.1)(47-50). Twenty-one school-children with BPD (mild, n = 9; 264 
moderate, n = 4; and severe, n = 8) were offered the opportunity to undergo high-resolution 265 
CT (HRCT) scans (47). The rate of severe BPD was higher compared to those not 266 
participating for scanning. Mean age of the children was 12.7 years (range: 8.7-16.7). Higher 267 
HRCT scores were related to lower Forced Expiratory Volume in 1 second (FEV1) (β -4.23; 268 
95% CI -6.97 to -1.49, p = 0.004) and Maximal Mid-Expiratory Flow (MMEF) (β -3.45; 95% CI 269 
-6.10 to -0.80, p = 0.013), but not to gas exchange as measured by CO diffusion capacity 270 
(DLCO). A retrospective study among 19 children with BPD observed that all children at a 271 
median age of 14.6 months (range 1.5-53.7) had CT abnormalities, which were not 272 
associated with clinical outcomes such as gestational age, type and duration of mechanical 273 
ventilation and BPD severity (48).  In a retrospective review, 41 very low birthweight infants 274 
with BPD, who had exacerbations in the last 6 months at a mean age, underwent HRCT 275 
scans and lung function tests at a mean age of 16 months. Maximal expiratory flow at 276 
functional residual capacity (VmaxFRC) and functional residual capacity (FRC) were 277 
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measured by the squeeze technique (50). An increased number of triangular subpleural 278 
opacities and of limited linear opacities on CT were associated with a lower FRC (r -0.426  279 
and -0.421 (p-value for both <0.02), respectively), but not VmaxFRC. A study among 40 280 
preterm born children (median age 27 weeks (range 24-32 weeks) observed that those 281 
remaining oxygen dependent at a post-conceptional age of 36 weeks had significantly higher 282 
chest radiograph scores at one of month of age (median 9, range 7 to 20) than those not 283 
chronically oxygen dependent (median 3, range 0 to 13); p<0.05 (49).  284 
 285 
Certainty of the evidence The certainty of the evidence was considered very low.  286 
 287 
Strength of the recommendation Conditional for the intervention. 288 
 289 
Task Force recommendation The Task Force suggests lung imaging to monitor children with 290 
BPD in subgroups only, for example children with severe BPD, severe respiratory symptoms, 291 
and/or recurrent hospital admissions due to respiratory morbidity (conditional 292 
recommendation based on very low certainty of evidence).  293 
 294 
Justification of recommendation Among the presented studies with indirect evidence to use 295 
lung imaging as a monitor tool, the study population consisted of children defined with the old 296 
form of BPD (51), the studies used retrospective or cross-sectional data collection with 297 
potential risk of bias, or reported not enough numerical data to be able to judge imprecision. 298 
Therefore, the evidence was considered very low. In clinical practice, Task Force members 299 
agreed that given the low certainty of evidence and potential side effects of radiation, 300 
monitoring with lung imaging would be justified only in subgroup of children with severe BPD, 301 
severe respiratory symptoms, recurrent hospitalizations or equivalent. For example, a chest 302 
CT with intravenous contrast could be considered to exclude other diagnoses, which may 303 
affect treatment strategies.  304 
 305 
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Other considerations Almost all children with established BPD seem to have lung structure 306 
abnormalities measured by lung imaging (50, 52). However, studies are mostly among 307 
children from an outpatient clinic, and proper control groups are often lacking. Also, the 308 
natural course of lung structural abnormalities and of normal alveolarization in early life is not 309 
fully known.  310 
 311 
Suggestions for future research Recently, nonionizing magnetic resonance imaging (MRI) 312 
scan protocols for children with BPD have been developed, and a quiet-breathing MRI scan 313 
independently assessed structural abnormalities of BPD, disease severity, and predicted 314 
short term outcomes at discharge from the neonatal intensive care unit (53, 54). This 315 
technique is a promising monitoring tool for long term outcomes. Further studies are 316 
warranted to examine the predictive value of lung imaging, preferably non-radiant, on long 317 
term outcomes of children with established BPD. Studies using lung imaging such as CT or 318 
MRI in the neonatal phase might be considered to better define the severity of BPD, or to 319 
diagnose or exclude other causes of BPD.  320 
 321 
Review of evidence addressing the question on lung function 322 
PICO 2 In children with BPD, does monitoring with lung function versus no lung function 323 
affect important and critical defined outcomes? 324 
 325 
Summary of the evidence No direct evidence that would answer this question in an 326 
appropriate way was identified. Indirect evidence was provided by two studies among 327 
preterm born children. The first study showed that among extremely preterm born children, 328 
the ratio of tidal expiratory flow at 50% of expired volume to peak tidal expiratory flow 329 
(TEF50/PTEF), which reflects airway obstruction, measured by electromagnetic inductance 330 
plethysmography predicts respiratory morbidity in the first year of life (Area Under Curve 331 
(95% Confidence Interval): 0.723 (0.55, 0.86)) (Supplementary Table 3.2)(55). Also, 332 
TEF50/PTEF was lower in the group with respiratory morbidity in the first year of life, than in 333 
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the group without (73.5 vs. 79.9, p-value = 0.03). Other tidal breathing lung function 334 
measures did not differ between those with and without respiratory morbidity. Another 335 
prospective cohort among 163 preterm born children measured tidal breathing and 336 
performed multiple breath washout measurements during sleep at the age of 44 weeks PMA 337 
(56). After adjustment for confounders, a higher respiratory rate and higher tidal volume were 338 
associated with a decreased and increased risk of wheeze, respectively, in the first year of 339 
life (OR (95% CI): 0.69 (0.50, 0.96) and 1.40 (1.04, 1.90), respectively), and a higher time to 340 
peak tidal expiratory flow expiratory time ratio (tPTEF/tE) with less bronchodilator inhalation 341 
therapy during the first year of life (OR (95% CI): 0.56 (0.35, 0.89)). Other lung function 342 
measures such as FRC and lung clearance index (LCI) were not associated with wheeze, 343 
inhalation therapy or re-hospitalization, and none of the lung function measures were 344 
associated with home oxygen therapy. The additional value of lung function tests was tested 345 
by adding them to prediction models for wheezing in the first year of life based on BPD 346 
classification, the clinical risk index for babies (CRIB) score, or clinical standard predictors 347 
such as sex, PMA and days of mechanical ventilation. Adding lung function to either of the 348 
three models however did not improve prediction of wheeze (AUC of model with vs. without 349 
added lung function (likelihood ratio test p-value) 0.63 vs 0.54 (0.15), 0.62 vs 0.52 (0.08) and 350 
0.71 vs 0.68 (0.12)).    351 
 352 
Certainty of evidence The certainty of the evidence was considered very low.  353 
 354 
Strength of the recommendation Conditional for the intervention.  355 
 356 
Task Force recommendation The Task Force suggests lung function to monitor children with 357 
BPD (conditional recommendation based on very low certainty of evidence). 358 
 359 
Justification of the recommendation No studies have been performed that examined the 360 
potential beneficial effect of lung function monitoring on important and critical defined 361 
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outcomes in children with BPD. Among the presented studies with indirect evidence to use 362 
lung function as a monitoring tool, the study population consisted of preterm born children, 363 
not specifically children with BPD, or potential confounders were not taken into account. 364 
Therefore, the evidence was considered very low. No evidence was found that monitoring 365 
children with BPD with lung function reduces morbidity and related outcomes. However, for 366 
clinical practice, Task Force members agreed that monitoring with lung function would be 367 
justified despite the lack of evidence. Lung function, specifically spirometry and related 368 
bronchodilator response at older ages, is an objective measure, is associated with lung 369 
function in adulthood, and with increased risks of morbidity and mortality, has sex, age, 370 
height, and ethnicity adjusted reference ranges, and has no potential side effects. Lung 371 
function could also act as a potential indicator for the risk of lung- and related vascular 372 
diseases in adulthood.  373 
 374 
Other considerations Many prospective and retrospective cohort studies have examined lung 375 
function at later ages among children with BPD (37, 57, 58), compared with preterm born 376 
children without BPD (37, 57, 58) or term born children (37). A recent meta-analysis of >50 377 
studies showed that children who were born preterm and were diagnosed with BPD had a 378 
16% lower FEV1, compared with children born at term (32). Similarly, a review of 18 studies 379 
showed that in those with BPD, compared with children born at term at age 6-19 years, FEV1 380 
was consistently lower (34). However, a large heterogeneity in results was observed 381 
suggesting variation in expression of the disease or differences in populations studied, with 382 
mostly diagnoses of the old form of BPD. Furthermore, also children born preterm without 383 
BPD or born preterm across the full gestational age range have a lower lung function at later 384 
age (32, 59), which suggests altered airway and lung maturation or mediation by specific 385 
ventilation strategies (60). Children with BPD often respond less to bronchodilators and have 386 
a lower fractional exhaled nitric oxide (FeNO), a measure of eosinophilic airway 387 
inflammation, compared with children with asthma (61, 62). This suggests that airway 388 
reactivity through eosinophilic airway inflammation is probably not involved in BPD. Previous 389 
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studies observed elevated neutrophils and oxidative stress in airways, measured by induced 390 
sputum and exhaled breath condensate respectively, in children aged 11 years or 391 
adolescents born preterm compared with children born term (63, 64). This suggests that BPD 392 
reflect an ongoing respiratory disease after birth with long-term consequences and not just 393 
stabilized structural lung damage after the neonatal period. The possible adverse effects of 394 
BPD on lung clearance index, a measure of ventilation heterogeneity of the lungs and a well-395 
accepted and applicable lung function test for children aged <5 years, and on exercise 396 
capacity are not fully clear (65-68). Some differences in lung function in early life have shown 397 
to be persistent in adulthood (69), which suggests that the expected optimal peak in lung 398 
function development is not reached. The relation of lung function measures with lung 399 
structure and risk of respiratory morbidity in children with BPD is not fully clear.  400 
Spirometry seems the most useful method for longitudinal follow up of lung growth and 401 
airway obstruction in school-age children with BPD. For preschool children (age <= 4 years) 402 
with BPD, the forced oscillation technique and multiple breath washout tests are the most 403 
applicable regarding technique and validity (43, 70). However, reported studies have small 404 
sample sizes and limitations, and the success rate in routine clinical practice without sedation 405 
is considered low. 406 
 407 
Suggestions for future research  Further studies, observational or RCT, are warranted to 408 
examine the predictive value of lung function on long term lung structure and respiratory 409 
morbidity of children with established BPD, and its value in monitoring responses to 410 
treatment.  411 
 412 
Review of evidence addressing the question on day care attendance 413 
PICO 3 In children with BPD, does discouraging day care attendance versus not 414 
discouraging day care attendance affect important and critical defined outcomes? 415 
 416 
Summary of the evidence  This could not be given because no articles were available. 417 
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 418 
Certainty of evidence The certainty of the evidence was considered very low.  419 
 420 
Strength of the recommendation Conditional for either the intervention or the comparison. 421 
 422 
Task Force recommendation The Task Force suggests to give individual advice to parents 423 
regarding day care attendance for children with BPD (conditional recommendation based on 424 
very low certainty of evidence).   425 
 426 
Justification of the recommendation Due to the lack of evidence, all Task Force members 427 
were asked what they would advise in their own clinical practice. Most do not discourage day 428 
care attendance, but do not encourage day care attendance either. The younger the child 429 
and the potentially higher prevalence of infectious diseases in specific seasons of the year, 430 
the more reluctant the Task Force members were to encourage day care attendance. The 431 
first winter in young, severely affected children with established BPD would be of most 432 
concern for attending day care. It was mentioned that day care attendance also has positive 433 
effects on e.g. social development. The Task Force group noted that parental leave 434 
regulations differ greatly among countries, for example 12 months in Scandinavian countries 435 
versus 3 months in The Netherlands, which could influence the decision to take the child to 436 
day care.  437 
 438 
Other considerations Advice should be based on local experience, age of the child, season 439 
of the year, and parental wishes and possibilities.  440 
 441 
Suggestions for future research Studies are needed to examine the effects of day care 442 
attendance on number and severity of respiratory symptoms, adverse growth, hospital 443 
admissions, duration of supplemental oxygen need, neurodevelopment and quality of life.  444 
 445 
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Review of evidence addressing the question on inhaled bronchodilators 446 
PICO 4 In children with BPD, does treatment with inhaled bronchodilators versus no inhaled 447 
bronchodilators affect important and critical defined outcomes? 448 
 449 
Summary of the evidence This could not be given because no articles were available.  450 
 451 
Certainty of the evidence The certainty of the evidence was considered very low. 452 
 453 
Strength of the recommendation Conditional recommendation for the intervention.  454 
 455 
Task Force recommendation The Task Force suggests treatment with bronchodilators for 456 
children with BPD in subgroups only, for example children with severe BPD, those with 457 
asthma-like symptoms, recurrent hospital admission due to respiratory morbidity, exercise 458 
intolerance, or reversibility in lung function (conditional recommendation based on very low 459 
certainty of evidence). 460 
 461 
Justification of the recommendation  Due to the lack of evidence, a discussion among the 462 
group members of the Task Forces was held on the use of inhaled bronchodilators in 463 
practice. It was suggested that treatment with inhaled bronchodilators is optional for 464 
subgroups only, e.g. for children with severe BPD, those with asthma-like symptoms, 465 
recurrent hospital admission due to respiratory morbidity, exercise intolerance, or 466 
bronchodilator reversibility in lung function. Potential benefits for some of these children have 467 
been experienced by Task Force group members. Some clinical practices start 468 
bronchodilators as a trial, and only continue if significant improvement in respiratory 469 
symptoms, lung function, if available, or number of hospitalizations or emergency visits is 470 
shown.  471 
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Other considerations Effects of treatment with inhaled bronchodilators should be carefully 472 
monitored by symptoms or lung function if applicable, or reduction of number of 473 
hospitalizations or emergency visits before chronically applied. 474 
 475 
Suggestions for future research Most studies have focused on treatment with bronchodilators 476 
of children before 36 weeks of PMA (71). Further studies are urgently needed to examine the 477 
use of inhaled bronchodilators in children with BPD. 478 
 479 
Review of evidence addressing the question on the use of inhaled/systemic 480 
corticosteroids 481 
PICO 5/6 In children in with BPD, does treatment with inhaled or systemic corticosteroids 482 
versus no inhaled or systemic corticosteroids affect important and critical defined outcomes? 483 
 484 
Summary of the evidence No direct evidence that would answer this question in an 485 
appropriate way was identified. Indirect evidence was obtained from one study, a crossover 486 
RCT that recruited eighteen children born premature (mean gestational age 28 weeks) at the 487 
age of 10.5 months, who had symptoms that were not controlled despite regular use of 488 
bronchodilators (72) (Supplementary Table 3.3). Children received either 200 μg of 489 
beclomethasone dipropionate or placebo twice daily for two six week periods, separated by a 490 
two-week washout period. During the active period, as compared to the placebo period, 491 
respiratory symptoms decreased (37% improvement in symptom score, p-value <0.001). 492 
During the active period, FRC increased significantly (30 vs 36 ml/kg, p < 0.002), while there 493 
was no change in FRC during the placebo treatment period (31 vs 32 ml/kg).  494 
 495 
Certainty of the evidence The certainty of the evidence was low. 496 
 497 
Strength of the recommendation Conditional against the intervention.  498 
 499 
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Task Force recommendation The Task Force suggests not to treat with inhaled or systemic 500 
corticosteroids for children with BPD (conditional recommendation based on low certainty of 501 
evidence). If the treating physician considers the use of inhaled/systemic corticosteroids of 502 
additional value, for example children with severe BPD, severe respiratory symptoms, 503 
recurrent hospitalizations or equivalent, and not controlled with regular use of 504 
bronchodilators, the effects of treatment with inhaled/systemic corticosteroids should be 505 
carefully monitored during a trial period before chronically applied.  506 
 507 
Justification of the recommendation Only one study was available, which was not specifically 508 
performed in children with the new form of BPD, but preterm born children who had 509 
uncontrolled respiratory symptoms. Additionally, loss to follow up was of methodological 510 
concern. Last, the use of corticosteroids may have side effects and/or can lead to adverse 511 
events, which need to be outweighed by the possible benefits. Therefore, the evidence was 512 
considered low. Since the use of corticosteroids may lead to side effects, the Task Force did 513 
not deem it justified to recommend treatment with inhaled corticosteroids.  514 
 515 
Other considerations Other evidence is provided by a cohort of 63 preterm born children, 516 
followed for 4 months, with a median age of 10 years at the time of the study (73). Those 517 
with bronchial obstruction, increased responsiveness to inhaled bronchodilators and/or 518 
abnormal diurnal peak expiratory flow (PEF) variation were included. In total 18 children met 519 
these criteria and received inhaled budesonide 0.8 mg-2 day -1 in two doses for the first 520 
month, followed by 0.4 mg-2 day -1 in two doses for another 3 months. Lung function was 521 
measured by spirometry twice daily at home, and at the clinic at baseline, after 1 months and 522 
after 4 months of budesonide treatment. Additionally, children kept a record of any 523 
respiratory symptoms, defined as cough or wheezing. Budesonide treatment did not lead to 524 
any changes in lung function measures at the clinic, although there was a decrease in diurnal 525 
peak expiratory flow (PEF) variation at home both after 1 and 4 months of budesonide 526 
treatment. The symptom score after 1 month of budesonide, but not after 4 months, was 527 
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significantly lower.  When the Task Force discussed the recommendations, it was taken into 528 
account that the indirect evidence for the use of corticosteroids was not strong, that there is a 529 
difference in using corticosteroids as standard treatment, or at the time of uncontrolled 530 
disease, and that corticosteroids should be used with caution, especially since the effects on 531 
preterm born, still growing lungs are not yet known. If the treating physician considers the 532 
use of inhaled/systemic corticosteroids of additional value, for example children with severe 533 
BPD, severe respiratory symptoms, recurrent hospitalizations or equivalent, and not 534 
controlled with regular use of bronchodilators, the effects of treatment with inhaled/systemic 535 
corticosteroids should be carefully monitored during a trial period before chronically applied. 536 
Monitoring could be by number and severity of symptoms, improvement of lung function, if 537 
applicable, or by number of hospitalizations or emergency visits.  538 
 539 
Suggestions for future research Further studies are urgently needed to examine the use of 540 
inhaled or systemic corticosteroids in children with BPD.   541 
 542 
Review of evidence directly addressing the question on diuretics  543 
PICO 7 In children in with BPD, does treatment with diuretics versus no diuretics affect 544 
important and critical defined outcomes? 545 
 546 
Summary of the evidence No direct evidence that would answer this question in an 547 
appropriate way was identified. Indirect evidence was provided by one study (74) 548 
(Supplementary Table 3.4). An RCT showed that, among infants with oxygen-dependent 549 
BPD who were clinically stable, there were no differences in number of rehospitalizations for 550 
respiratory deterioration (diuretic group 22 of 14 patients vs. placebo group 19 of 6 patients), 551 
pulmonary function tests, or total duration of supplemental oxygen use (diuretic group 133+/-552 
53 days vs.  placebo group 147 +/- 71 days), and no differences in side effects including 553 
nephrocalcinosis, supplemental electrolytes or hearing deficits between the groups after 36 554 
weeks of PMA. Only FRC measured between 9 weeks after weaned from oxygen and 555 
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diuretics and 1 year of corrected age gestational age was increased in the diuretics group. At 556 
1 year of corrected gestational age, the FRC/TGV had improved in both the diuretic group 557 
(0.89±0.18) and the placebo group (0.97±0.11). 558 
 559 
Certainty of the evidence The certainty of the evidence was considered very low.  560 
 561 
Strength of the recommendation Conditional for either the intervention or the comparison.  562 
 563 
Task Force recommendation  For those children with BPD who already received treatment 564 
with diuretics from the neonatal phase or neonatal intensive care unit onwards, the Task 565 
Force suggests natural weaning by the relative decrease in dose with increasing weight gain 566 
(conditional recommendation based on very low certainty of evidence). If the treating 567 
physician considers the use of diuretics of additional value, for example when clinical signs of 568 
fluid retention are present, the effects of treatment with diuretics should be carefully 569 
monitored during a trial period before chronically applied.  570 
 571 
Justification of the recommendation No intervention studies examined the potential beneficial 572 
effect of diuretics on important and critical defined outcomes in children in whom BPD has 573 
been established and were discharged from the hospital, or who were older than 36 weeks of 574 
PMA. In the presented study, the exact method of randomization procedure was unclear, 575 
potential confounders were not taken into account, the intention to treat analysis was not fully 576 
clear, and additional furosemide supplementation differed between the groups (diuretic group 577 
0/22 patients vs placebo group 5/21 patients; p-value <0.05). The study group did not contain 578 
children with the new form of  BPD. Therefore, the evidence was considered very low.  579 
 580 
Other considerations None.  581 
 582 
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Suggestions for future research Further studies are needed to examine the use of diuretics in 583 
children with BPD. 584 
 585 
Review of evidence directly addressing the question oxygen 586 
PICO 8 In children with BPD, does treatment with oxygen versus no oxygen affect important 587 
and critical defined outcomes? 588 
 589 
Summary of the evidence This could not be provided because no articles were available. 590 
 591 
Certainty of the evidence The certainty of the evidence was considered very low. 592 
 593 
Strength of the recommendation Conditional recommendation for the intervention 594 
 595 
Task Force recommendation The Task Force suggests for children with BPD that 596 
supplemental oxygen with a minimum saturation target level of 90% should be maintained 597 
until further studies are performed (conditional recommendation based on very low certainty 598 
of evidence).  599 
 600 
Justification of the recommendation  In a study among children born <30 weeks of gestation 601 
who were still dependent on supplemental oxygen at 32 weeks of gestation were randomized 602 
into target saturation range 91-94% vs. 95-98% (75). This study found no difference in 603 
growth (weight, length, head circumference at 38 weeks PMA or corrected age of 12 months, 604 
or weight and length <10th percentile, or head circumference <3rd percentile), re-605 
hospitalization rate, retinopathy of prematurity stage 3 or 4, major developmental abnormality 606 
(blindness, cerebral palsy, or general quotient on revised Griffiths Mental Developmental 607 
Scale <2 SD below mean), psychosocial measures or death. Children with higher target 608 
saturation did have longer duration of oxygen use, compared to children with lower target 609 
saturation. A review of the literature concluded that no studies showed a conclusive proof of 610 
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the optimal target saturation in post-term oxygen therapy in children born preterm on several 611 
outcomes (76). Saturation targets used were not uniform across different studies. The 612 
suggestion was that saturation levels below 90% should be avoided, and that levels above 613 
92-94% might be protective against adverse effects. We consider a minimum threshold of 614 
90% SpO2, not lower, since a recent review of the literature found no studies that showed a 615 
conclusive proof of the optimal target saturation in post-term oxygen therapy in children born 616 
preterm for beneficial effects on several health outcomes (76). Our suggestion of using a cut-617 
off value of 90% SpO2 for considering home oxygen is based on low-grade evidence, as is 618 
the minimum threshold of 93% as stated in a recent ATS guideline (77). A cut-off value of 619 
90% SpO2 instead of 93% SpO2 will require fewer infants to be discharged on home oxygen 620 
therapy, which alleviates a relative financial burden of health care systems’ resources without 621 
running an unduly high risk of compromising patient outcomes. However, we do emphasize 622 
on the need of future studies to define the optimal saturation targets for children in whom 623 
BPD already has been established and are discharged from the hospital, or who were older 624 
than 36 weeks of PMA, also taking potential effects on non-pulmonary outcomes into 625 
account.  626 
 627 
Other considerations The BOOST II trial, an international RCT comparing an oxygen 628 
saturation target of 85-89% with 91-95% for children born before 28 weeks of gestation, 629 
demonstrated that a saturation target below 90% was associated with an increased risk of 630 
death before discharge (78). This finding led to an early stop of the trial. Results of studies 631 
comparing different saturation targets on health outcomes after discharge are lacking. The 632 
recent published British Thoracic Society guideline on supplementary home oxygen found C 633 
and D levels of evidence (of A to D categories) for supplementary oxygen in children with 634 
chronic neonatal lung disease to reduce or prevent pulmonary hypertension, reduce 635 
intermittent desaturations, reduce airway resistance, promote growth and neurodevelopment, 636 
and to possible reduce associated risk of sudden unexplained death in infancy. Home 637 
oxygen treatment should be recommended as oxygen at home is preferable to a prolonged 638 
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hospital stay for both quality of life and psychological impact for the infant, parents and 639 
family, and as it saves days in hospital due to earlier discharge despite a significant 640 
readmission rate. Specific saturation targets are not provided. The American Thoracic 641 
Society guideline on home oxygen therapy for children recommends home oxygen therapy 642 
for patients with BPD complicated by chronic hypoxemia, based on very low-quality evidence 643 
(77). Home oxygen therapy seems to increase growth rate, short-term oxygen use 644 
decreased mean pulmonary artery pressure, and nocturnal oxygen use improved sleep 645 
duration and decreased arousal. The utility of home monitoring on informing temporary 646 
decline of BPD is not fully known.  647 
 648 
Suggestions for future research Further studies are urgently needed to examine the optimal 649 
saturation targets of oxygen use in children with BPD. 650 
 651 
General considerations The new form of BPD is characterized predominantly by an arrest 652 
in development of airways and lungs, specifically alveoli, pulmonary vascular development, 653 
and to a lesser extent by iatrogenic lung damage (27). Clinically, the new form of BPD is 654 
defined as oxygen need for ≥28 days from birth until 36 weeks of PMA (27). However, this 655 
definition of BPD is currently under debate as the pathological process of BPD is a sliding 656 
scale, may also be present in preterm born children without BPD, and does not seem to 657 
allow prediction of outcomes. In the future, potentially biomarkers in blood and exhaled 658 
breath, lung function in early life, clinical parameters and quiet-breathing MRI scan may all 659 
dependent or independent of each other help to better define BPD and predict short term 660 
outcomes, and additionally long-term outcomes and treatment responses (53). As a 661 
consequence of the initial for identifying monitoring and treatment strategies for the current 662 
ERS guideline, not every new and promising avenue of monitoring or treatment could 663 
ultimately be pursued. It may therefore require future updates to integrate new emerging 664 
monitoring and treatment strategies, as for example long term monitoring and treatment of 665 
pulmonary hypertension in children with BPD, which is suggested to be an underdiagnosed 666 
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condition (79-82). Pediatric cardiologists should therefore be more intensively involved in 667 
multi-disciplinary follow-up of children with BPD from discharge into adulthood. Future 668 
research should not be limited to children with BPD but should also include children born 669 
across the full range of gestational age.  670 
For children born <32 weeks of gestational age, BPD severity is based on the amount of 671 
oxygen need at 36 weeks of PMA, or discharge to home (28, 83). An objective, reliable and 672 
safe test for BPD severity is the ‘oxygen reduction test’, a standardized assessment of 673 
oxygen saturation during a timed stepwise reduction of administered oxygen to room air (84). 674 
Objectively determining the severity of BPD may be important for identifying children most at 675 
risk for later lung, pulmonary vascular, or other sequelae, implying that more close 676 
monitoring and treatment might be needed. 677 
Additionally to the considered and rated outcomes, extremely preterm born children are 678 
at increased risks of adverse ophthalmologic and renal outcomes. The development or 679 
deterioration of retinopathy of prematurity in our defined population was considered very 680 
small but cannot be excluded for late-onset retinopathy. Therefore, retinopathy of prematurity 681 
warrants close monitoring specifically when discussing saturation limits if supplemental 682 
oxygen is needed. Future studies are warranted to examine interventions related to 683 
monitoring and treatment of adverse rental outcomes (85). Additionally, the incidence of 684 
chronic pulmonary vascular disease in children and adults born preterm in the new BPD era 685 
are not fully clear. Results from studies among children born within the old and new BPD era 686 
suggest that they have an increased risk of subclinical pulmonary hypertensive vascular 687 
disease, exercise induced pulmonary hypertension, right ventricular dysfunction, and 688 
autonomic dysfunction (81, 86-89). Protocols for screening and diagnosing these adverse 689 
health outcomes, specifically pulmonary hypertensive vascular diseases have recently been 690 
suggested (80, 82, 90). As with any lung disease or general health, exposure to smoking 691 
should be strongly discouraged and omitted.   692 
In line with this Task Force, a workgroup among experts held by the National Institute of 693 
Child Health and Human Development in the US concluded that there is an urgent need of 694 
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studies on postnatal management to decrease the severity of BPD, improve respiratory and 695 
medication management of established BPD including BPD associated pulmonary 696 
hypertension, and to obtain more information on the long term outcomes of BPD (91). 697 
Prospective, structured, standardized and multi-disciplinary follow-up of children with BPD 698 
from discharge into adulthood is needed, and may help to generate important data for future 699 
monitoring and treatment studies. It depends on the (regions) of countries if neonatologists 700 
alone monitor and treat children with BPD for much longer than immediately after discharge. 701 
Some countries have set-up a multidisciplinary outpatient clinic for children with severe BPD 702 
with equally and important involvement of subspecialists, including pediatric-pulmonologists, 703 
neonatologists, pediatric-cardiologists, ear-nose-throat physicians, physiotherapists, 704 
psychologists, and social workers/case managers. Transition of such care systems into 705 
adulthood is needed, and research related to these multidisciplinary clinics may lead to new 706 
insights and improve long-term outcomes (92, 93).  707 
Studies on monitoring or treatment of children with BPD are challenging. BPD is a rare 708 
disease, and preterm born children are a vulnerable group of children hampering clinical 709 
trials. Also, relevant health outcomes at a young age are difficult to define, and long-term 710 
follow up studies are ideally needed. Similarly, studies on the long term airway, lung, and 711 
vascular driven pathophysiology related to gestational age at birth, ventilation and oxygen 712 
concentration strategies leading to potential BPD subtypes in older children or adults are 713 
lacking. According to the Task Force members, all efforts should be made to design and 714 
perform studies in children with BPD to improve quality of life and prevent short- and long-715 
term consequences across the life course.    716 
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SUMMARY 717 
The Task Force utilized comprehensive syntheses to inform its judgments regarding the 718 
balance of desirable (benefits) and undesirable (burden, adverse effects) consequences of 719 
the intervention, certainty of the evidence, and values, and made conditional 720 
recommendations for all interventions. We suggest monitoring with lung imaging using 721 
ionising radiation in a subgroup only, for example severe BPD, severe symptoms, recurrent 722 
hospitalizations (conditional recommendation based on very low certainty of evidence), and 723 
monitoring with lung function in all children (conditional recommendation based on very low 724 
certainty of evidence). The Task Force suggests to give individual advice to parents 725 
regarding day care attendance (conditional recommendation based on very low certainty of 726 
evidence). With regards to treatment, the Task Force suggests treatment with 727 
bronchodilators in a subgroup only, for example children with severe BPD, asthma-like 728 
symptoms, and/or recurrent hospital admissions due to respiratory morbidity (conditional 729 
recommendation based on very low certainty of evidence), while treatment with inhaled or 730 
systemic corticosteroids is not suggested (conditional recommendation based on low 731 
certainty of evidence). The Task Force suggests not to start diuretics in children with BPD 732 
unless clinical signs for fluid retention are present, and for those children with BPD who 733 
already received treatment with diuretics from the neonatal phase or neonatal intensive care 734 
unit onwards, the Task Force suggests natural weaning by the relative decrease in dose with 735 
increasing weight gain (conditional recommendation based on very low certainty of 736 
evidence). The Task Force suggests supplemental oxygen with a minimum saturation target 737 
of 90% (conditional recommendation based on very low certainty of evidence). A 738 
multidisciplinary approach for children with established severe BPD with involvement of 739 
subspecialists from discharge after the neonatal period into adulthood is desirable. These 740 
recommendations should be considered until new and urgently needed evidence becomes 741 
available. 742 
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Table 1. Outcomes defined as “important” or “critical” for decision-making for each PICO question related to the intervention for children with 
BPD. 
 
 Outcome 
Intervention  
Monitoring with lung imaging Number and severity of respiratory symptoms, adverse growth, hospital admissions, reduced physical 
exercise capacity, prolonged duration of supplemental oxygen need, side effects, adverse 
neurodevelopment, decreased quality of life, mortality, or impaired lung function  
Monitoring with lung function  Number and severity of respiratory symptoms, hospital admissions, CT abnormalities, reduced physical 
exercise capacity, use of inhaled bronchodilators, use of inhaled corticosteroids, use of systemic 
corticosteroids, prolonged duration of supplemental oxygen need, adverse neurodevelopment, quality of 
life, or mortality 
Discourage daycare attendance Number and severity of respiratory symptoms, adverse growth, hospital admissions, prolonged duration 
of supplemental oxygen need, adverse neurodevelopment, quality of life, or mortality 
Treatment with inhaled bronchodilators Number and severity of respiratory symptoms, hospital admissions, reduced physical exercise capacity, 
prolonged duration of supplemental oxygen need, quality of life, mortality, or impaired lung function 
Treatment with inhaled/systemic corticosteroids Number and severity of respiratory symptoms, adverse growth, hospital admissions, reduced physical 
exercise capacity, pulmonary hypertension, prolonged duration of supplemental oxygen need, side 
effects, adverse neurodevelopment, quality of life, mortality, or impaired lung function 
Treatment with diuretics Number and severity of respiratory symptoms, hospital admissions, pulmonary hypertension, prolonged 
duration of supplemental oxygen need, side effects, adverse neurodevelopment, quality of life, mortality, 
or impaired lung function 
Treatment with oxygen Number and severity of respiratory symptoms, adverse growth, hospital admissions, reduced physical 
exercise capacity, pulmonary hypertension, prolonged duration of supplemental oxygen need, side 
effects, adverse neurodevelopment, quality of life, mortality, or impaired lung function 
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Table 2. Interpretation of the strength of the recommendations (94) 
Implications Strong recommendation Conditional (weak) recommendation 
For patients Most individuals in this situation would want the 
recommended course of action and only a small 
proportion would not. Formal decision aids are not 
likely to be needed to help individuals make decisions 
consistent with their values and preferences. 
The majority of individuals in this situation would want the 
suggested course of action, but many would not. 
For clinicians Most individuals should receive the intervention. 
Adherence to this recommendation according to the 
guideline could be used as a quality criterion or 
performance indicator. 
Recognize that different choices will be appropriate for 
individual patients and that clinicians must help each 
patient arrive at a management decision consistent with 
his or her values and preferences. Decision aids may be 
useful helping individuals making decisions consistent 
with their values and preferences. 
For policy makers The recommendation can be adapted as policy in 
most situations 
Policy making will require substantial debate and 
involvement of various stakeholders. 
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Table 3. Recommendations for the monitoring and treatment of children with BPD (details of the recommendations are provided in main text).  
 
Question Recommendation Strength  Quality of evidence 
1 We suggest monitoring with lung imaging using ionising radiation in a subgroup only (e.g. 
children with severe course of BPD, severe respiratory symptoms, and/or recurrent hospital 
admissions due to respiratory morbidity).   
Conditional Very low 
2 We suggest monitoring with lung function. Conditional Very low 
3 We suggest to give individual advice to parents regarding day care attendance.  Conditional Very low 
4 We suggest that treatment with bronchodilators could be optional for subgroups (e.g. children 
with severe course of BPD, severe respiratory or asthma-like symptoms, recurrent hospital 
admission due to respiratory morbidity, exercise intolerance, or reversibility in lung function).  
Conditional Very low 
5/6 We suggest no treatment with inhaled or systemic corticosteroids.  Conditional Low 
7 We suggest natural weaning of diuretics by the relative decrease in dose with increasing weight 
gain. 
Conditional Very low 
8 We suggest supplemental oxygen with saturation target range of 90-95%. Conditional  Very low 
 
